Welcome to our dedicated page for Damora Therapeutics SEC filings (Ticker: DMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Damora Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Damora Therapeutics's regulatory disclosures and financial reporting.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported a Form 4 showing a grant of stock options linked to Fairmount-managed investment vehicles. An option for 37,313 shares of common stock with a $23.05 exercise price was awarded and is held indirectly by Peter Harwin for one or more Fairmount funds.
The option vests in equal monthly installments through March 23, 2029, contingent on Harwin’s continued service to Damora. Under his arrangement with Fairmount, any net cash or stock from this option must be turned over to Fairmount for the benefit of the relevant Fairmount fund, and the parties disclaim beneficial ownership beyond their pecuniary interest.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.
Damora Therapeutics, Inc. director Turtle Cameron filed an initial statement of beneficial ownership on Form 3. The filing reports no purchases, sales, grants, gifts, or other transactions, and shows no derivative positions or holdings disclosed in this dataset.
Damora Therapeutics, Inc. director Michael Landsittel filed an initial ownership report on Form 3. This filing establishes his status as a reporting insider and provides a baseline record of his holdings in Damora Therapeutics, although no specific transactions or share amounts are detailed in the available data.
Damora Therapeutics announced a major leadership and board refresh. The Board appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and she will also join the Board. Her offer includes a $695,000 base salary, a target bonus equal to 55% of salary, 500,000 restricted stock units vesting over four years, and options to purchase 1,500,000 shares vesting over four years, with enhanced severance and accelerated vesting protections around a change in control.
Current COO Sherwin Sattarzadeh will step down as principal executive officer but remain Chief Operating Officer. Directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigned, with their equity awards fully accelerated, and the Board size was reduced from seven to six. Michael Landsittel and Cameron Turtle were appointed as Class III directors and will receive options under the 2026 Equity Incentive Plan, while Peter Harwin was named Board chair. Damora also updated compensation and severance terms for General Counsel Garrett Winslow, including a $440,000 salary, a 40% target bonus and options for 250,000 shares.
Damora Therapeutics is repositioning as a hematology-focused biopharmaceutical company built around antibodies targeting mutant calreticulin (mutCALR) in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, is a monoclonal antibody engineered for higher potency against Type 1 and Type 2 mutCALR and longer half-life than a reference mutCALR antibody with the same mechanism as INCA033989, aiming to enable convenient subcutaneous dosing.
The company plans to file IND or CTA submissions for DMR-001 in mid-2026 and start a Phase 1 trial in ET and MF, with proof‑of‑concept readouts expected beginning mid‑2027. Follow-on candidates DMR-002 and DMR-003 are designed to broaden coverage across the mutCALR disease spectrum, with planned regulatory filings in the second half of 2026 and in 2027, respectively.
Damora acquired private “Pre‑Acquisition Damora” via a stock‑for‑stock asset acquisition and assumed an extensive option and research collaboration with Paragon Therapeutics, including options on DMR‑001, DMR‑002 and DMR‑003. To fund this strategy, it completed a $285 million PIPE in November 2025 and a follow‑on underwritten offering raising approximately $297.3 million in net proceeds in February 2026, alongside a new $150.0 million at‑the‑market program.